Study found lapatinib combined with an aromatase inhibitor (AI) and trastuzumab combined with an AI to be clinically more effective than AI monotherapy for the first-line treatment of patients who have hormone receptor-positive/human epidermal growth factor 2-positive metastatic breast cancer. However, neither of these treatments are cost-effective compared with AIs alone.